KRAS Q61 (rare in melanoma; NRAS Q61 is more common) — MEKi monotherapy modest activity (...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-Q61-MELANOMA |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CIVIC SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | KRAS Q61X |
| Disease | DIS-MELANOMA |
| ESCAT tier | IIB |
| Evidence summary | KRAS Q61 (rare in melanoma; NRAS Q61 is more common) — MEKi monotherapy modest activity (binimetinib in NRAS-mut melanoma NEMO trial; KRAS Q61 cells extrapolated). |
Notes
ESCAT IIB. Encoded under BIO-RAS-MUTATION (no variant-specific BIO for KRAS Q61X yet). FLAG: dedicated BIO-KRAS-Q61X would improve granularity.
Used By
No reverse references found in the YAML corpus.